updated results of phase i/ii bruin study: pirtobrutinib in covalent btk inhibitor pretreated mcl
Published 1 year ago • 112 plays • Length 1:56Download video MP4
Download video MP3
Similar videos
-
1:55
update on the phase i/ii bruin study
-
1:32
genomic evolution & resistance to pirtobrutinib in covalent btk inhibitor pre-treated cll
-
0:55
updated results of the bruin trial: pirtobrutinib in r/r mcl
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
2:25
results from a phase i/ii trial of pirtobrutinib and lv20.19 for patients with r/r lymphomas
-
2:49
results from the phase iii echo trial of acalabrutinib plus br in mcl
-
5:15
the only meaningful treatment for mild cognitive impairment
-
1:08:14
17.11 what's new upgrade webinar
-
3:46
how to update istat analyser @abbott point of care
-
2:58
results of a phase ib study of ibrutinib obinutuzumab in r/r cll
-
3:35
new phase iii trial of imetelstat versus bat in jak inhibitor-refractory myelofibrosis
-
1:25
preliminary results from a phase ib trial of as-1763, a novel non-covalent btki, in cll/mcl
-
2:23
results from the phase ii elm-2 trial: odronextamab for r/r follicular lymphoma
-
3:46
firmware update video
-
1:39
phase i/ii trial of adct-602 in b-all
-
0:47
overview of the phase iii enhance trial schema
-
2:13
brdu replacement: click-it™ edu technology is the best for measuring dna synthesis by flow cytometry
-
2:14
long-term follow-up results from the rathl trial: response-adapted treatment for advanced stage hl
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
1:52
evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
-
14:25
progress report iv - réka ehrenberger
-
3:21
ash 2022 lba: results from the ecog-acrin e1910 trial